Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease

Mukherjee, Soumya; Seal, Manas; Dey, Somdatta
December 2014
Journal of Biological Inorganic Chemistry;Dec2014, Vol. 19 Issue 8, p1355
Academic Journal
Serotonin (5-HT) is an essential neurotransmitter for cognitive functions and formation of new memories. A deficit in 5-HT dependent neuronal activity is somewhat specific for Alzheimer's disease. Metal-mediated oxidative degradation of neurotransmitters by Aβ bound to metals has been investigated. Heme-bound Aβ is found to catalyze the oxidative degradation of 5-HT leading to the formation of neurotoxic products dihydroxybitryptamine and tyrptamine-4,5-dione. The catalytic degradation of 5-HT is of first order with respect to both heme-Aβ and HO, and the maximum rate of 5-HT oxidation is obtained at physiological pH (pH 7-7.5). pH perturbation of the binding affinity of heme-Aβ complex for 5-HT indicates that the binding of the substrate (5-HT) is not the rate-determining step. Arg5 acts as a second-sphere residue facilitating the O-O bond cleavage, the mutation of which leads to a decrease in the rate of 5-HT oxidation. The pull effect of the Arg5 residue tends to facilitate the generation of the active oxidant, Compound I, below neutral pH, while the ionization of the phenol group of the substrate facilitates the generation of the active substrate above neutral pH. A combination of these two opposing effects results in the highest activity at physiological pH. Apart from the Arg5 residue, the Tyr10 residue is found to play a vital role in the 5-HT oxidation by heme-Aβ complexes.


Related Articles

  • Role of Serotonin in Alzheimer's Disease. Geldenhuys, Werner I.; Van der Schyf, Cornelis I. // CNS Drugs;2011, Vol. 25 Issue 9, p765 

    Mounting evidence accumulated over the past few years indicates that the neurotransmitter serotonin plays a significant role in cognition. As a drug target, serotonin receptors have received notable attention due in particular to the role of several serotonin-receptor subclasses in cognition and...

  • An Overview of the Current and Novel Drugs for Alzheimer's Disease with Particular Reference to Anti-Cholinesterase Compounds. Colombres, Marcela; Sagal, Juan Paulo; Inestrosa, Nibaldo C. // Current Pharmaceutical Design;Oct2004, Vol. 10 Issue 25, p3121 

    Several cellular processes could be targeted if the complex nature of Alzheimer' s disease (AD) was already understood. Most of AD treatments have been focused on the inhibition of acetylcholinesterase (AChE) in order to raise the levels of its substrate, i.e. the neurotransmitter acetylcholine...

  • New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimer's Disease? Maillet, Marjorie; Robert, Sylvain J.; Lezoualc'h, Frank // Current Alzheimer Research;Apr2004, Vol. 1 Issue 2, p79 

    The serotonin 5-HT4 receptor mediates many physiological effects in the central nervous system. The recent molecular identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the...

  • Adjunctive treatment with high frequency repetitive transcranial magnetic stimulation for the behavioral and psychological symptoms of patients with Alzheimer's disease: a randomized, double-blind, sham-controlled study. Yue WU; Wenwei XU; Xiaowei LIU; Qing XU; Li TANG; Shuyan WU // Shanghai Archives of Psychiatry;Oct2015, Vol. 27 Issue 5, p280 

    Background: Behavioral and psychological symptoms of dementia (BPSD) occur in 70-90% of patients at different stages of Alzheimer's Disease (AD), but the available methods for managing these problems are of limited effectiveness. Aim: Assess the effects of high-frequency repetitive transcranial...

  • Music therapy for Alzheimer's patients. Asselstine, J.; Kristman, V. L. // Maladies Chroniques et Blessures au Canada;Nov2016, Vol. 36 Issue 11, p264 

    Introduction: Music therapy (MT) is an attractive, non-pharmacological treatment for many individuals suffering from dementia. It is well established that MT is responsible for many mood-boosting effects in Alzheimer's disease (AD) patients; however it is unclear whether these benefits extend to...

  • The Effect of Catecholamine Depletion by Alpha-Methyl-Para-Tyrosine on Measures of Cognitive Performance and Sleep in Abstinent MDMA Users. McCann, Una D.; Peterson, Stephen C.; Ricaurte, George A. // Neuropsychopharmacology;Aug2007, Vol. 32 Issue 8, p1695 

    (±) 3, 4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug of abuse and a brain serotonin (5-HT) neurotoxin in animals. Growing evidence suggests that humans who use MDMA recreationally can also develop 5-HT neurotoxic injury, although functional consequences have been...

  • Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD): An Update [1]. Gualtieri, Fulvio; Guandalini, Luca; Manetti, Dina; Martini, Elisabetta; Romanelli, Maria Novella // Medicinal Chemistry Reviews - Online;Dec2005, Vol. 2 Issue 6, p471 

    Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and agerelated pathologies such as MCI and AD. Development of cognition...

  • A Prospective, Open-Label, 12 Week Trial of S-adenosylmethionine in the Symptomatic Treatment of Alzheimer's Disease. Rudolph, Maja L.; Rabinoff, Michael; Kagan, Bruce L. // Neuroscience & Medicine;Sep2011, Vol. 2 Issue 3, p222 

    Objective: To determine if treatment with S-adenosylmethionine (SAM-e) might lead to cognitive and behavioral improvement in patients with Alzheimer's disease (AD). Interventions: We conducted a prospective, open-label study of six subjects who were given oral SAM-e over 12 weeks and measured...

  • Neurochem: beating Alzheimer's via beta-amyloid.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p4 

    Reports that the United States Alzheimer Association has highlighted Neurochem Inc.'s Alzhemed as a promising treatment for Alzheimer's disease. Percentage of patients who had stabilized or improved in cognitive function tests after several months of treatment; Reduction in cerebrospinal fluid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics